A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk.

Vinayak, S.,Schwartz, E. J.,Jensen, K.,Lipson, J.,Alli, E.,McPherson, L.,Fernandez, A. M.,Sharma, V. B.,Staton, A.,Mills, M. A.,Schackmann, E. A.,Telli, M. L.,Kardashi...; Breast Cancer Res. Treat.. 2013 Oct 30.

Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase.

Alli, E., Sharma, V.B., Sunderesakumar, P., Ford, J.M.; Cancer Res. 2009-04-15.

CBP Is a dosage-dependent regulator of nuclear factor-kappaB suppression by the estrogen receptor.

Nettles, K.W., Gil, G., Nowak, J., Métivier, R., Sharma, V.B., Greene, G.L.; Mol Endocrinol. 2008 Feb.